Mutz Christopher 4

What Happened

• Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), was granted a restricted stock award of 21,306 shares on 2026-02-26 valued at $77.15 per share (total value ≈ $1,643,758).
• On 2026-02-28, 2,221 shares were disposed (withheld) at $73.90 per share to cover tax liabilities (value ≈ $164,132). The primary transaction is an award (compensation), which is different from an open-market purchase or sale.

Key Details

• Grant date and amount: 21,306 restricted shares on 2026-02-26 at $77.15 each (≈ $1,643,758).
• Tax withholding: 2,221 shares withheld on 2026-02-28 at $73.90 each (≈ $164,132); reported as code F (payment of exercise price or tax liability).
• Vesting: The 21,306 restricted shares vest in four equal annual installments on the first through fourth anniversaries of Feb 26, 2026 (footnote F1).
• Additional note: Filing references share-withholding exempt under Rule 16(b)-3 related to the vesting of 4,342 previously reported restricted shares (footnote F2).
• Shares owned after the transactions: not specified in this filing.
• Filing timeliness: the form lists these transactions for the reporting period ending 2026-02-26 and was filed 2026-03-02; the filing does not state a late-filing flag.

Context

• This was a compensation-related restricted stock grant that vests over multiple years (not an open-market purchase). Withholding of shares to cover taxes is routine and typically treated as exempt from short-swing profit rules under Rule 16(b)-3. Such awards signal company compensation to align executives with shareholder interests but are not in themselves a direct bullish or bearish market action.